Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

Inclusion Criteria:

• Age older than 1 month to younger than 18 years.

• Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.

• Immunophenotyping: acute B-lymphoblastic leukemia;

• Meet one of the following situations:

A. Provisional low-risk: D19MRD ≥ 0.1%; B. Provisional intermediate-risk: D19MRD ≥ 0.01%;

• Subjects in the sytudy group or their guardians must be able to understand andaccept the informed consent approved by the Ethics Committee

Exclusion Criteria:

• sIgM+;

• ALL evolved from chronic myeloid leukemia (CML);

• Down's syndrome, or major congenital or hereditary disease with organ dysfunction;

• Other secondary leukemias;

• CNS involvement;

• History of epilepsy; or convulsions within the last month;

• Known underlying congenital immunodeficiency or metabolic disease;

• Congenital heart disease with cardiac insufficiency;

• Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for > 7 dayswithin one month before enrollment, or any chemotherapy or radiotherapy within 3months before enrollment (except for emergency radiotherapy to relieve airwaycompression);

• Initial diagnosis of high risk;

• D46MRD ≥1%.